Peptide Initiative

Peptide profile · Weight Management

Pramlintide

Synthetic amylin analog for comprehensive postprandial glucose control with insulin therapy

Strong human trialsFDA approved for this use
~48 minutesHalf-life
30-40% subcutaneous bioavailabilityBioavailability
3,949Molecular weight, Da

Molecular formula

C171H267N51O53S2

CAS number
196078-30-5
PubChem
70691388
Developed · 1996
Amylin Pharmaceuticals (AstraZeneca), Amylin Pharmaceuticals / AstraZeneca

Amino acid sequence

KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY-NH2 (Pro25, Pro28, Pro29 substitutions; Cys2-Cys7 disulfide)

Blood Sugar ControlPowerful postprandial glucose regulation through glucagon suppression, gastric emptying delay, and satiety — addressing the amylin deficiency component of diabetes

0.9

Weight ManagementClinically meaningful weight loss of 1-2 kg through centrally mediated satiety, particularly beneficial for insulin-treated patients who typically gain weight

0.7

Metabolic HealthRestores the amylin arm of glucose homeostasis that is lost in insulin-dependent diabetes, enabling more physiological glucose regulation

0.7

Ratings out of 10.

15 – 120mcg

Every documented dose level

PhaseDoseFrequency
Titrate up after 3+ days without significant nausea15 mcg per meal (type 1 diabetes)Immediately before each major meal
Ongoing, as tolerated30-60 mcg per meal (type 1 diabetes)Immediately before each major meal
Increase to 120 mcg after 3+ days without significant nausea60 mcg per meal, titrating to 120 mcg (type 2 diabetes)Immediately before each major meal
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for improving postprandial glucose control in insulin-treated diabetes & reducing insulin dose requirements while maintaining glycemic control

Best for

  • Improving postprandial glucose control in insulin-treated diabetes

    Pramlintide is particularly well-suited for individuals focused on improving postprandial glucose control in insulin-treated diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Reducing insulin dose requirements while maintaining glycemic control

    Pramlintide is particularly well-suited for individuals focused on reducing insulin dose requirements while maintaining glycemic control. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Supporting weight management in insulin-treated T1DM and T2DM patients

    Pramlintide is particularly well-suited for individuals focused on supporting weight management in insulin-treated t1dm and t2dm patients. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Addressing amylin deficiency in insulin-dependent diabetes

    Pramlintide is particularly well-suited for individuals focused on addressing amylin deficiency in insulin-dependent diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

Consider alternatives if

Alternative approaches for weight management supportConsult your healthcare provider for alternatives to Pramlintide based on your specific needs and medical history
Alternative weight management approachesSemaglutide (Wegovy/Ozempic)Liraglutide (Saxenda)AOD-9604
Non-injectable weight managementOral semaglutide (Rybelsus)Phentermine-topiramate (Qsymia)Lifestyle modifications

Do not use if

  • Confirmed gastroparesis requiring treatment
  • Hypoglycemia unawareness (inability to recognize hypoglycemic symptoms)
  • Known hypersensitivity to pramlintide or metacresol
  • Pediatric patients (safety not established in children)

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Pramlintide use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare Pramlintide with similar peptides to find the best fit for your goals.

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

The Pramlintide injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.

3 common side effects · 2 serious

Emergency signs first, then what this page and MedlinePlus say.

FDA-approved pramlintide demonstrates good tolerability in insulin-treated diabetes with well-characterized safety profile from >20 years clinical use.

Gastrointestinal side effects (nausea) occur in 30-50% of initiators but typically resolve within 1-3 weeks. Hypoglycemia risk, especially when combined with insulin, requires dose coordination and patient education.

Pancreatic side effects theoretically possible but not documented in clinical trials. Pregnancy category C requires careful consideration.

FDA approval supported by diabetes randomized trials (n=1000+) demonstrating HbA1c reductions of 0.5-1.0% with weight loss of 1-2 kg over 6 months.

Mechanistic studies via stable-isotope glucose tracer methodology show slowed gastric emptying (50-60% reduction in gastric output rate) and inhibited glucagon secretion. Postprandial glucose improvements measured at 2-3 hours post-meal with 40-50 mg/dL average reductions versus placebo.


Common side effects · experienced by some users

Nausea

The most common side effect, affecting 30-50% of patients during initiation. Usually mild to moderate and related to pramlintide's gastric emptying effects. Typically transient.

Management
Start at the lowest recommended dose and titrate slowly. Nausea generally resolves within 1-2 weeks. Eat smaller meals. If severe, pause titration or temporarily reduce dose. Do not increase dose until nausea subsides.

Reduced Appetite / Anorexia

Decreased appetite is reported in 10-15% of patients and is a consequence of pramlintide's central satiety-promoting mechanism in the hypothalamus and area postrema .

Management
This effect often contributes to the desired weight loss benefit. Ensure adequate caloric and nutritional intake. If excessive or concerning, consult healthcare provider about dose adjustment.

Headache

Reported in approximately 5-13% of patients. Often occurs during the initiation phase and may be related to metabolic adjustments or blood glucose fluctuations.

Management
Usually resolves with continued treatment. Standard analgesics may be used. Ensure blood glucose is stable — headache may indicate hypo- or hyperglycemia requiring glucose review.

Serious side effects

Severe Hypoglycemia (BLACK BOX WARNING)

The most clinically significant risk. Pramlintide is used with insulin, and the combined glucose-lowering effect can cause severe hypoglycemia, particularly in the first weeks. The FDA mandates a 50% reduction in mealtime insulin at pramlintide initiation .

Management
CRITICAL: Reduce mealtime rapid-acting or pre-mixed insulin by 50% when starting pramlintide. Use frequent blood glucose monitoring (pre- and post-meals). Have rapid-acting glucose available. Consider continuous glucose monitoring. Gradually retitrate insulin based on blood glucose patterns.

Less commonAbdominal Pain and VomitingInjection Site Reactions

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Pramlintide
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Pramlintide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeInsulin (Rapid-Acting) — Essential co-administration — pramlintide is only indicated for use alongside mealtime insulin. Reduces required insulin dose while improving postprandial control.
  • SafeInsulin Glargine — Basal insulin provides fasting glucose coverage while pramlintide addresses postprandial glucose spikes and insulin dose optimization
  • SafeMetformin — In type 2 diabetes, metformin's insulin-sensitizing action complements pramlintide's postprandial glucose control and weight benefit

With medications

  • CautionSulfonylureas — Increased risk of severe hypoglycemia due to non-glucose-dependent insulin secretion combined with pramlintide's glucose-lowering effects
  • CautionAlpha-Glucosidase Inhibitors — Both agents slow gastric emptying and nutrient absorption, potentially leading to excessive GI side effects and unpredictable glucose patterns
  • CautionGLP-1 Receptor Agonists — Overlapping mechanisms of gastric emptying delay and appetite suppression with increased GI side effects and hypoglycemia risk

With supplements

  • SafeMultivitamins — Generally safe to take alongside Pramlintide. Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Strong human trials · first signs weeks 1-2

Evidence level

Strong human trials

(Phase 3 or FDA approved)

100/100

Regulatory status

FDA approved for this use

Onset of effects

Moderate

(1-2 weeks)


How it works

Pramlintide is a synthetic copy of amylin, a hormone your pancreas naturally makes alongside insulin.

It slows down how fast food leaves your stomach, tells your brain when you're full, and stops your liver from releasing too much glucose after meals. Think of it as a helper hormone that works with insulin to keep blood sugar steady and help you lose weight.

The deeper mechanism

Pramlintide is a 37-amino acid synthetic amylin analog (Pro25, Pro28, Pro29-substituted human amylin) that acts as a selective amylin receptor agonist, activating amylin receptor 1 (AmyR1)—a heteromeric receptor complex composed of calcitonin receptor (CALCR) and receptor activity-modifying protein 1 (RAMP1).

At peripheral sites, amylin receptor activation on vagal afferents suppresses postprandial glucagon secretion through a glucose-dependent mechanism and delays gastric emptying via direct effects on gastric smooth muscle innervation, both reducing postprandial glucose excursions.

Centrally, amylin receptors in the hypothalamus (particularly in the ventromedial hypothalamus and amygdala) mediate appetite suppression and promote satiety signaling, contributing to reduced food intake and weight loss.

Unlike insulin (which is glucose-independent and can cause hypoglycemia), amylin's glucagon suppression only occurs when blood glucose is elevated, providing inherent hypoglycemia protection.

Pramlintide also enhances energy expenditure through central mechanisms and may have neuroprotective effects, with emerging evidence suggesting amylin may play a role in preventing cognitive decline associated with diabetes.


What to expect

  1. Weeks 1-2

    What you might notice

    • Reduced postprandial glucose spikes, possible nausea, reduced appetite
    • Blood glucose may be lower than expected — monitor closely due to 50% insulin dose reduction

    What's normal

    • Nausea is very common and expected
    • Blood glucose patterns will change significantly
    • You may feel less hungry after meals
    • Some patients notice flatter post-meal glucose curves within the first few days

    What's next

    • Continue at starting dose
    • Begin gradual insulin retitration based on blood glucose data
    • If nausea resolves, prepare for dose escalation as tolerated
  2. Weeks 3-8

    What you might notice

    • Improving postprandial glucose control, diminishing nausea, early weight stabilization or loss, ability to titrate to maintenance dose

    What's normal

    • Nausea typically resolves by week 3-4
    • Appetite suppression continues but becomes manageable
    • Insulin doses are gradually being retitrated upward toward optimal glycemic targets
    • Weight may begin to decrease

    What's next

    • Achieve and maintain target maintenance dose (120 mcg T2DM or 60 mcg T1DM per meal)
    • Fine-tune insulin dosing based on blood glucose patterns
  3. Weeks 12-24

    What you might notice

    • Stable glycemic control with reduced HbA1c, sustained weight loss of 1-2 kg, reduced overall insulin requirements compared to baseline

    What's normal

    • HbA1c reduction of 0
    • 6% is typical
    • Weight loss plateaus at 1-2 kg
    • Postprandial glucose excursions are significantly reduced
    • Mealtime insulin doses are typically 10-30% lower than pre-pramlintide levels after retitration

    What's next

    • Continue maintenance therapy with ongoing blood glucose monitoring
    • Reassess HbA1c every 3 months
    • Adjust insulin as needed for sustained optimal control

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Pramlintide over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

60 registered studies, 4 still enrolling.

60registered studies
4recruiting now
18phase 3 or 4
19with published results

By phase

Phase 2

15

Phase 4

10

Phase 3

6

Phase 1

3

Phase 2/3

2

Early Phase 1

2

Phase 1/2

1

No phase

21

A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.

What kind of research

Gave the drug

59

Records only

1

About 4,559 people took part in the studies that actually administered Pramlintide. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.


Most recent

  • NCT07679516 Not Yet Recruiting15 enrolled

    Postprandial Regulation of Bone Perfusion in Healthy Individuals

    University of Copenhagen

  • NCT07506369 Recruiting18 enrolled

    Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans

    University Hospital, Gentofte, Copenhagen

  • NCT07340788 Not Yet Recruiting21 enrolled

    Amylin-Induced Migraine Attacks Without Aura

    Danish Headache Center

See all 60 trials for Pramlintide

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Pramlintide is named as an intervention; studies that only mention it in passing are not.

Why does pramlintide have a BLACK BOX WARNING?

Pramlintide carries an FDA BLACK BOX WARNING for severe hypoglycemia because it is always used in combination with insulin. The combined glucose-lowering effects can cause dangerous drops in blood sugar, particularly during the first weeks of therapy. To mitigate this risk, the FDA mandates that mealtime insulin doses be reduced by 50% when starting pramlintide. Close blood glucose monitoring is essential, and patients must have rapid-acting glucose available at all times.

What is amylin and why is pramlintide needed?

Amylin (islet amyloid polypeptide) is a hormone naturally co-secreted with insulin by pancreatic beta cells after meals. It plays a crucial role in glucose regulation by suppressing glucagon, slowing gastric emptying, and promoting satiety. In type 1 diabetes, amylin is completely absent due to beta cell destruction. In advanced type 2 diabetes, amylin secretion is severely impaired. Pramlintide replaces this missing hormone, restoring a key component of normal glucose homeostasis that insulin alone cannot address.

Can pramlintide be mixed with insulin in the same syringe?

No, pramlintide must never be mixed with any type of insulin. The pH of pramlintide solution is different from insulin formulations, and mixing can alter the pharmacokinetics of both drugs. Pramlintide and insulin must be administered as separate injections at separate injection sites, at least 2 inches apart.

Why were proline substitutions made to create pramlintide from native amylin?

Native human amylin has a strong tendency to self-aggregate and form amyloid fibrils (the same fibrils found in pancreatic islet amyloid deposits in type 2 diabetes). This aggregation makes native amylin pharmaceutically unstable and unsuitable as a drug. The three proline substitutions at positions 25, 28, and 29 were based on rat amylin, which naturally contains prolines at these positions and does not aggregate. These substitutions disrupt the beta-sheet formation that drives amyloid aggregation while preserving full biological activity at amylin receptors.

Is pramlintide suitable for all patients with diabetes?

No. Pramlintide is specifically indicated for patients with type 1 or type 2 diabetes who are already on mealtime insulin therapy and have not achieved adequate postprandial glucose control. It is contraindicated in patients with gastroparesis, hypoglycemia unawareness, and those who cannot reliably comply with the critical insulin dose reduction requirements. It is not a standalone therapy and is not appropriate for patients not using insulin.

How does pramlintide differ from GLP-1 receptor agonists?

While both pramlintide and GLP-1 receptor agonists slow gastric emptying and promote satiety, they work through entirely different receptor systems. Pramlintide activates amylin receptors (AMY1/2/3), while GLP-1 RAs activate the GLP-1 receptor. Key differences include: pramlintide must be given with insulin (adjunctive only), GLP-1 RAs can be used independently; pramlintide suppresses glucagon via amylin receptors, GLP-1 RAs stimulate glucose-dependent insulin secretion; pramlintide has a very short half-life (~48 min) requiring injection before each meal, while most modern GLP-1 RAs are once-weekly.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Pramlintide, on one page.

Pramlintide dosing protocol

Medical disclaimer

Pramlintide is FDA approved for the use described here. It is a prescription medication that should only be started, adjusted, or stopped under the supervision of a qualified healthcare provider. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 12, 2026

15 – 120 mcg Immediately before each major meal · onset 1-2 weeks
Open the Pramlintide calculatorPramlintide calculator